Floatz logo

DARATUMUMAB

Testosterone Greater Than 150 ng/dL

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Testosterone Greater Than 150 ng/dL cohort.

Asset / SponsorPhaseRating
Osilodrostat
Johns Hopkins University
Phase 4BBB
Anakinra
University Hospital, Basel, Switzerland
Phase 3BB
Metyrapone
Mayo Clinic
Phase 2CCC
Edicotinib
M.D. Anderson Cancer Center
Phase 1C
Semaglutide
University of Texas Southwestern Medical Center
N/AD
Solu-Cortef
University of Minnesota
Phase 1NR

Same molecule, other indications

DARATUMUMAB is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
smoldering plasma cell myelomaDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →